BDSX Insider Trading

Insider Ownership Percentage: 69.20%
Insider Buying (Last 12 Months): $393,500.00
Insider Selling (Last 12 Months): $134,963.43

Biodesix Insider Trading History Chart

This chart shows the insider buying and selling history at Biodesix by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$2M-$1M$0$1M$2MTotal Insider BuyingTotal Insider Selling

Biodesix Share Price & Price History

Current Price: $0.55
Price Change: Price Decrease of -0.0046 (-0.83%)
As of 04/17/2025 05:00 PM ET

This chart shows the closing price history over time for BDSX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMarApr$0.55Closing price on 04/17/25:

SEC Filings (Institutional Ownership Changes) for Biodesix (NASDAQ:BDSX)

20.96% of Biodesix stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at BDSX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$3.78Mbought$526ksoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$4M-$2M$0$2M$4MTotal InflowsTotal Outflows
Biodesix logo
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.
Read More on Biodesix

Today's Range

Now: $0.55
Low: $0.54
High: $0.58

50 Day Range

MA: $0.75
Low: $0.53
High: $0.99

52 Week Range

Now: $0.55
Low: $0.51
High: $2.04

Volume

348,570 shs

Average Volume

292,720 shs

Market Capitalization

$80.14 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.17

Who are the company insiders with the largest holdings of Biodesix?

Biodesix's top insider shareholders include:
  1. Jack W Schuler (Director)
  2. Matthew Strobeck (Director)
  3. John Patience (Chairman)
  4. Scott Hutton (CEO)
  5. Robin Harper Cowie (CFO)
  6. Gary Anthony Pestano (Insider)
  7. Ryan H Siurek (CAO)
  8. Kieran O'kane (Insider)
  9. Chris Vazquez (CAO)
Learn More about top insider investors at Biodesix.